# A Study of HS-20089 in Patients With Advanced Solid Tumors

> **NCT05263479** · PHASE1 · RECRUITING · sponsor: **Shanghai Hansoh Biomedical Co., Ltd** · enrollment: 177 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HS-20089 (Phase Ia：Dose escalation )
- **DRUG:** HS-20089 (Phase Ib: Dose expansion)

## Key facts

- **NCT ID:** NCT05263479
- **Lead sponsor:** Shanghai Hansoh Biomedical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-05
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263479, "A Study of HS-20089 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05263479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*